Fung Simon, Blair Hannah A
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Target Oncol. 2023 Mar;18(2):287-294. doi: 10.1007/s11523-023-00952-y. Epub 2023 Feb 24.
Abemaciclib [Verzenio (USA) or Verzenios (EU)] is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor approved in combination with adjuvant endocrine therapy for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), node-positive, early breast cancer with a high risk of recurrence. In a phase III trial, abemaciclib plus endocrine therapy reduced the risk of recurrence of breast cancer compared with endocrine therapy alone, including in patients who had previously received neoadjuvant chemotherapy, in patients with high- and low-scoring Ki-67 tumours, and in both premenopausal and postmenopausal patients. The tolerability profile of abemaciclib plus endocrine therapy was acceptable and manageable, with diarrhoea, infections and neutropenia being the most common adverse events. Thus, abemaciclib in combination with standard endocrine therapy is a valuable additional treatment option for patients with HR+, HER2-, node-positive early breast cancer with a high risk of recurrence.
阿贝西利[维择（美国）或唯择（欧盟）]是一种细胞周期蛋白依赖性激酶4和6（CDK4/6）抑制剂，被批准与辅助内分泌治疗联合用于激素受体阳性（HR+）、人表皮生长因子受体2阴性（HER2-）、淋巴结阳性、具有高复发风险的早期乳腺癌患者。在一项III期试验中，与单纯内分泌治疗相比，阿贝西利联合内分泌治疗降低了乳腺癌复发风险，包括既往接受过新辅助化疗的患者、Ki-67肿瘤评分高和低的患者，以及绝经前和绝经后患者。阿贝西利联合内分泌治疗的耐受性良好且可控，腹泻、感染和中性粒细胞减少是最常见的不良事件。因此，对于HR+、HER2-、淋巴结阳性且具有高复发风险的早期乳腺癌患者，阿贝西利联合标准内分泌治疗是一种有价值的额外治疗选择。
